Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory drug (IMiD) presented as a tablet for oral use. It is indicated for the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes with del(5q), mantle cell lymphoma and follicular lymphoma in adult patients.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Lenalidomide is used in the management of hematologic cancers and related blood disorders. - Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and prolongs survival. - Mantle Cell Lymphoma: enhances overall response when combined with standard chemotherapy. - Follicular Lymphoma: contributes to disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil count. - Thrombocytopenia: low platelet levels. - Anemia: decreased red blood cells. - Fatigue: persistent tiredness. - Nausea: upset stomach and vomiting. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: heightened infection risk. - Severe thrombocytopenia: increased bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: elevated liver enzymes and liver dysfunction.

Before initiating Lenalidomide therapy, several precautionary measures should be observed. - Pregnancy: contraindicated (Category X); ensure effective contraception for both male and female patients. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation when risk factors are present. - Renal impairment: evaluate kidney function and adjust dose as recommended. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias early. - Drug interactions: review concomitant medications for potential interactions that may affect efficacy or safety. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Live vaccines: increased risk of infection; avoid concurrent administration. - Anticoagulants (warfarin): may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin, clopidogrel): monitor for bleeding complications. - Other immunomodulatory agents (e.g., pomalidomide): additive myelosuppression possible. - NSAIDs: may affect renal function, especially in patients with pre‑existing kidney disease.